Search results
Results from the WOW.Com Content Network
Large-cell lung carcinoma (LCLC), or large-cell carcinoma (LCC) in short, is a heterogeneous group of undifferentiated malignant neoplasms that lack the cytologic and architectural features of small cell carcinoma and glandular or squamous differentiation. [1]
Many small series have suggested that the prognosis of lung tumors with giant cells is worse than that of most other forms of non-small-cell lung cancer (NSCLC), [11] including squamous cell carcinoma, [42] and spindle cell carcinoma. [42] The overall five-year survival rate in GCCL varies between studies but is generally considered to be very low.
Lung cancers are now considered a large and extremely heterogeneous family of neoplasms [4] that feature widely varying genetic, biological, and clinical characteristics. . About 50 different lung cancer variants are recognized under the 2004 revision of the World Health Organization ("WHO-2004") histological typing system, the most widely recognized and used lung cancer classification sche
The authors concluded that trials using a patient mix weighted toward good prognosis will not find such a difference. In 1993, a retrospective analysis was performed on 2031 patients with aggressive non-Hodgkin's lymphoma, of all ages, treated with a doxorubicin -based chemotherapy regimen such as CHOP between 1982 and 1987. [ 2 ]
Approximately 98% of lung cancers are carcinoma, a term for malignant neoplasms derived from cells of epithelial lineage, and/or that exhibit cytological or tissue architectural features characteristically found in epithelial cells. [8] Under WHO-2004, lung carcinomas are divided into 8 major taxa: [1] Squamous cell carcinoma; Small cell carcinoma
Basaloid forms of lung carcinoma were first described in the peer-reviewed medical literature by Dr. Elisabeth Brambilla and her colleagues in 1992. [11] They were first recognized as distinct clinicopathological variants of both squamous cell and large cell lung cancers in 1999, within the third revision of the World Health Organization lung tumor typing and classification scheme.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Acinar adenocarcinoma of the lung is a highly lethal disease. Overall, the five-year survival rates approximate 16% to 22%. Generally, survival is better in all stages for patients with the acinar (or papillary) pattern than it is in patients with the solid pattern, but considerably worse than those with the bronchioloalveolar pattern.